Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
80.02
-0.81 (-1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
December 09, 2021
From
AstraZeneca
Via
Business Wire
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
December 08, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
December 03, 2021
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
November 30, 2021
From
AstraZeneca
Via
Business Wire
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
November 18, 2021
From
AstraZeneca
Via
Business Wire
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
November 17, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
November 05, 2021
From
AstraZeneca
Via
Business Wire
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
November 01, 2021
From
AstraZeneca
Via
Business Wire
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
November 03, 2021
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...
Via
FinancialNewsMedia
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
November 01, 2021
From
AstraZeneca
Via
Business Wire
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
October 25, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
October 20, 2021
From
AstraZeneca
Via
Business Wire
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
October 15, 2021
From
AstraZeneca
Via
Business Wire
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
October 08, 2021
From
AstraZeneca
Via
Business Wire
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
October 05, 2021
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
October 04, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
September 29, 2021
From
AstraZeneca HealthCare Foundation
Via
Business Wire
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
September 27, 2021
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
September 24, 2021
From
AstraZeneca
Via
Business Wire
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
September 23, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
September 17, 2021
From
AstraZeneca
Via
Business Wire
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
September 17, 2021
From
AstraZeneca
Via
Business Wire
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
September 09, 2021
From
AstraZeneca
Via
Business Wire
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
September 09, 2021
From
AstraZeneca
Via
Business Wire
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
August 31, 2021
From
AstraZeneca
Via
Business Wire
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
August 20, 2021
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.